Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM × anti-CD3)

Gynecologic Oncology

Volumn 138, Issue 2, 2015, Pages 343-351

  Fossati, Marco ^a   Buzzonetti, Alexia ^a   Monego, Giovanni ^a   Catzola, Valentina ^a   Scambia, Giovanni ^a   Fattorossi, Andrea ^a   Battaglia, Alessandra ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bispecific monoclonal antibody; Catumaxomab; Immunomodulatory activity; Malignant ascites

Indexed keywords

CATUMAXOMAB; CD38 ANTIGEN; CD69 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERLEUKIN 2; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; PREDNISOLONE;

ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION ASSAY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MALIGNANT ASCITES; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ASCITES; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; ILEAL NEOPLASMS; ILEOCECAL VALVE; IMMUNOLOGY; INFUSION; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; OVARIAN NEOPLASMS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; T LYMPHOCYTE; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CELL LINE, TUMOR; FEMALE; HUMANS; ILEAL NEOPLASMS; ILEOCECAL VALVE; INFUSIONS, PARENTERAL; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MACROPHAGE ACTIVATION; MACROPHAGES; OVARIAN NEOPLASMS; PREDNISOLONE; T-LYMPHOCYTES;

EID: 84938199116     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.06.003     Document Type: Article

References (40)

1. A.A. Ayantunde, and S.L. Parson Pattern and prognostic factors in patients with malignant ascites: a retrospective study Ann. Oncol. 18 2007 945 949
2. S.L. Parsons, S.A. Watson, and R.J. Steele Malignant ascites Br. J. Surg. 83 1996 6 14
3. E. Smolle, V. Taucher, and J. Haybaeck Malignant ascites in ovarian cancer and the role of targeted therapeutics Anticancer Res. 34 2014 1553 1561
4. P. Ruf, and H. Lindhofer Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody Blood 98 2001 2526 2534
5. P. Ruf, O. Gires, M. Jäger, K. Fellinger, J. Atz, and H. Lindhofer Characterisation of the new EpCAM specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer Br. J. Cancer 97 2007 315 321
6. R. Zeidler, J. Mysliwietz, M. Csánady, A. Walz, I. Ziegler, B. Schmitt, and et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells Br. J. Cancer 83 2000 261 266
7. M.A. Ströhlein Catumaxomab treatment significantly improves overall survival in patients with malignant ascites: follow-up results from a pivotal phase II/III study (abstract) Proceeding of the 22nd International Congress on Anticancer Treatment Feb. 2011 1 4 (Paris, France)
8. A. Burges, P. Wimberger, C. Kümper, V. Gorbounova, H. Sommer, B. Schmalfeldt, and et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study Clin. Cancer Res. 13 2007 3899 3905
9. M.M. Heiss, P. Murawa, P. Koralewski, E. Kutarska, O.O. Kolesnik, V.V. Ivanchenko, and et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial Int. J. Cancer 127 2010 2209 2221
10. M. Jäger, A. Schoberth, P. Ruf, J. Hess, M. Hennig, B. Schmalfeldt, and et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) Cancer Res. 72 2012 24 32
11. D. Atanackovic, H. Reinhard, S. Meyer, S. Spöck, T. Grob, T. Luetkens, and et al. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting Hum. Vaccin. Immunother. 12 2013 2533 2542
12. B. Melichar, C.A. Savary, R. Patenia, S. Templin, K. Melicharova, and R.S. Freedman Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma Int. J. Gynecol. Cancer 13 2003 435 443
13. A. De Leonardis, A. Casamassima, E. Chiuri, L. Addabbo, N. De Frenza, and G. Falco Lymphocytic subpopulations in malignant ascites of ovarian origin. Flow cytometric analysis Minerva Ginecol. 45 1993 291 300
14. + cells with platinum resistance Gynecol. Oncol. 106 2007 75 81
15. Y. Fumita, F. Tanaka, F. Saji, and K. Nakamuro Immunosuppressive factors in ascites fluids from ovarian cancer patients Am. J. Reprod. Immunol. 6 1984 175 178
16. M. Onsrud Immunosuppressive effects of peritoneal fluids from ovarian cancer patients Gynecol. Oncol. 23 1986 316 322
17. A.D. Santin, P.L. Hermonat, A. Ravaggi, S. Bellone, J.J. Roman, C.V. Smith, and et al. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer Gynecol. Obstet. Investig. 51 2001 254 261
18. R.L. Giuntoli, T.J. Webb, A. Zoso, O. Rogers, T.P. Diaz-Montes, R.E. Bristow, and et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity Anticancer Res. 29 2009 2875 2884
19. E. Tran, J.S. Nielsen, D.A. Wick, A.V. Ng, L.D. Johnson, N.J. Nesslinger, and et al. Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines PLoS One 5 2010 e15625
20. J. Sehouli, P. Wimberger, I.B. Vergote, P. Rosenberg, A. Schneeweiss, C. Bokemeyer, and et al. Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: results from the phase IIIb CASIMAS study J. Clin. Oncol. 30 2012 (Suppl.; abstr e13097)
21. G. Ferrandina, F.O. Ranelletti, F. Legge, V. Salutari, E. Martinelli, A. Fattorossi, and et al. Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer Clin. Cancer Res. 12 2006 2055 2060
22. A. Fattorossi, A. Battaglia, G. Ferrandina, A. Buzzonetti, F. Legge, V. Salutari, and et al. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients Gynecol. Oncol. 92 2004 106 115
23. E. Fasano, S. Serini, E. Piccioni, S. Trombino, A. Toesca, G. Monego, and et al. DHA induces apoptosis by altering the expression and cellular location of GRP78 in colon cancer cell lines Biochim. Biophys. Acta 2012 1822 1762 1772
24. B. Barleon, S. Sozzani, D. Zhou, H.A. Weich, A. Mantovani, and D. Marmé Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 Blood 87 1996 3336 3343
25. A. Mantovani, R. Bonecchi, and M. Locati Tuning inflammation and immunity by chemokine sequestration: decoys and more Nat. Rev. Immunol. 6 2006 907 918
26. C. Murdoch, A. Giannoudis, and C.E. Lewis Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues Blood 104 2004 2224 2234
27. S. Soker, H.Q. Miao, M. Nomi, S. Takashima, and M. Klagsbrun VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding J. Cell. Biochem. 85 2002 357 368
28. R.P. Kruger, J. Aurandt, and K.L. Guan Semaphorins command cells to move Nat. Rev. Mol. Cell Biol. 6 2005 789 800
29. J.A. Hollenbaugh, and R.W. Dutton IFN-γ regulates donor CD8 T cell expansion, migration, and leads apoptosis of cells of a solid tumor J. Immunol. 177 2006 3004 3011
30. D. Goèrè, C. Flament, S. Rusakiewicz, V. Poirier-Colame, O. Kepp, I. Martins, and et al. Potent immunomodulatory effects of the trifunctional antibody catumaxomab Cancer Res. 73 2013 4663 4673
31. K. Dettmar, I. Seitz-Merwald, C. Lindemann, P. Schroeder, D. Seimetz, and J. Atz Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM × anti-CD3) treatment in vivo Clin. Transl. Oncol. 14 2012 376 381
32. M.T. Lotze, M.C. Custer, and S.A. Rosenberg Intraperitoneal administration of interleukin-2 in patients with cancer Arch. Surg. 121 1986 1373 1379
33. J. Markowska, J.K. Lacki, J. Jaroszewski, and K. Wiktorowicz The usefulness of CD4/CD8 ratio evaluation in monitoring of ovarian cancer patients Eur. J. Gynaecol. Oncol. 16 1995 54 58
34. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends Immunol. 23 2002 549 555
35. A.J. Cochran, R.R. Huang, J. Lee, E. Itakura, S.P. Leong, and R. Essner Tumour-induced immune modulation of sentinel lymph nodes Nat. Rev. Immunol. 6 2006 659 670
36. A. Cipponi, M. Mercier, T. Seremet, J.F. Baurain, I. Théate, J. van den Oord, and et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases Cancer Res. 72 2012 3997 4007
37. R. Zeidler, G. Reisbach, B. Wollenberg, S. Lang, S. Chaubal, B. Schmitt, and et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing J. Immunol. 163 1999 1246 1252
38. R. Punnonen, K. Teisala, T. Kuoppala, B. Bennett, and J. Punnonen Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors Cancer 83 1998 788 796
39. R.L. Robson, R.M. McLoughlin, J. Witowski, P. Loetscher, T.S. Wilkinson, S.A. Jones, and N. Topley Differential regulation of chemokine production in human peritoneal mesothelial cells: IFN-gamma controls neutrophil migration across the mesothelium in vitro and in vivo J. Immunol. 167 2001 1028 1038
40. Y. Osuga, K. Koga, Y. Hirota, T. Hirata, O. Yoshino, and Y. Taketani Lymphocytes in endometriosis Am. J. Reprod. Immunol. 65 2011 1 10